+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID07890714

Evaluating Datopotamab Deruxtecan with Other Cancer Agents for Solid Tumors in a Phase 12 Master Protocol Trial

Led by Daiichi Sankyo · Updated on 2026-10-22

268

Participants Needed

1

Research Sites

17 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, tolerability, and antitumor activity of Datopotamab Deruxtecan Dato-DXd combined with other anticancer agents or alone in participants with solid tumors, specifically focusing on urothelial cancer and KRAS-mutant non-small cell lung cancer. The study includes two independent substudies, each with dose finding Phase 1 and signal finding Phase 2 phases to assess treatment effects and safety. Participants receive Dato-DXd intravenously combined with either enfortumab vedotin EV with or without pembrolizumab for urothelial cancer, or with the KRAS G12C inhibitor olomorasib orally for non-small cell lung cancer. Treatments are given according to dosing schedules determined in early study phases, with different groups receiving combinations or monotherapies based on tumor type and phase. During the study, participants undergo monitoring for adverse events, tumor response, and other clinical outcomes over approximately 2.9 years. Assessments include tumor imaging, laboratory tests, and evaluation of drug concentrations and immune responses. The research team tracks dose-limiting toxicities, treatment-related side effects, and tumor shrinkage to evaluate treatment impact and safety. Participants are followed for survival and disease control throughout the study period.

CONDITIONS

Brief Title

A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)]

Research Team

C

Contact for Trial Information

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here